Building the future of individualised medicines
We are in a unique time where we now have the technology to find patients with genetic conditions and design medicines to treat them at the source. But this often requires customization to a small number of patients, something our current system of population-focused medicine was not designed for.
As we face a global crisis of genetic disease, affecting millions of children alone with rare conditions, we have a moral imperative to ensure equitable access to 21st century technologies, irrespective of the number of patients that could benefit from them.
OUR PURPOSE
Founded on the principle that the UK is well suited to model this new system of individualised medicines, the Rare Therapies Launch Pad (RTLP) was set up in 2023 as a ground-breaking pilot programme to help put in place the processes and infrastructure to bridge the gap between the patients and the science, giving children and their families a chance at a longer, healthier life together.